CML and Novacta to collaborate on biocatalysis development
Cambridge Major Laboratories (CML), a global service-based chemistry outsourcing partner to the pharma and biotech industries, and Novacta Biosystems of Welwyn Garden City, UK are to collaborate on combining their respective expertise in process development, custom synthesis and biocatalysis.
Cambridge Major Laboratories (CML), a global service-based chemistry outsourcing partner to the pharma and biotech industries, and Novacta Biosystems of Welwyn Garden City, UK are to collaborate on combining their respective expertise in process development, custom synthesis and biocatalysis.
Under the agreement, Novacta will develop biocatalytic approaches to target chiral intermediates, which CML will then scale-up in facilities in Weert, the Netherlands.
"Novacta Biosystems is recognised as an expert in its field, with a strong practical focus. CML is well-known for its pragmatic approach and problem-solving skills. Together we will be able to bring to bear a formidable range of chemistry tools. It is an exciting opportunity for CML and for our clients," said Roger McDonald, European business development director at CML.
"We feel there are many opportunities to develop more selective, cost-effective and greener solutions to API manufacture,' added Dr Georg Buchner, vp of corporate development at Novacta.
CML specialises in chemical process development and advanced multi-step organic synthesis, and operates from four facilities in the US and Europe. The company has been FDA inspected and approved for cGMP manufacturing.